Moderately hypofractionated radiotherapy, both isodose and dose-escalated, led to progression-free survival outcomes similar to that achieved with conventionally fractionated radiotherapy in patients ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

UHF noninferior to conventionally fractionated radiotherapy for men with intermediate- to high-risk localized disease. (HealthDay News) — Ultra-hypofractionated (UHF) radiotherapy delivered over two ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

According to data from two phase III trials presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium, patients with high-risk prostate cancer had a significantly ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post ...

Evaluation of post radiotherapy PSA as a prognostic and predictive biomarker in high risk prostate cancer: A secondary analysis of RTOG 0521. Results of AFU-GETUG-20: A randomised phase 3 trial of ...

Prostate cancer is the most commonly diagnosed cancer in the UK. But screening is not universal, and charities are divided over whether it should be extended. What do those living with the disease ...

The 2 groups--those receiving ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy--had similar overall survival, which was 81% and 79%, respectively, at 10 years.